WO2000058509A3 - Prostate cancer associated human fibronectin gene and biallelic markers - Google Patents

Prostate cancer associated human fibronectin gene and biallelic markers Download PDF

Info

Publication number
WO2000058509A3
WO2000058509A3 PCT/IB2000/000431 IB0000431W WO0058509A3 WO 2000058509 A3 WO2000058509 A3 WO 2000058509A3 IB 0000431 W IB0000431 W IB 0000431W WO 0058509 A3 WO0058509 A3 WO 0058509A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
prostate cancer
biallelic markers
fibronectin gene
cancer associated
Prior art date
Application number
PCT/IB2000/000431
Other languages
French (fr)
Other versions
WO2000058509A2 (en
Inventor
Marta Blumenfeld
Lydie Bougueleret
Ilya Chumakov
Annick Cohen-Akenine
Original Assignee
Genset Sa
Marta Blumenfeld
Lydie Bougueleret
Ilya Chumakov
Annick Cohen-Akenine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genset Sa, Marta Blumenfeld, Lydie Bougueleret, Ilya Chumakov, Annick Cohen-Akenine filed Critical Genset Sa
Priority to AU41356/00A priority Critical patent/AU4135600A/en
Publication of WO2000058509A2 publication Critical patent/WO2000058509A2/en
Publication of WO2000058509A3 publication Critical patent/WO2000058509A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Abstract

The invention concerns the genomic sequence of the Fibronectin gene. The invention also concerns biallelic markers of a Fibronectin gene and the association established between these markers and cancer, particularly prostate cancer. The invention provides means to determine the predisposition of individuals to cancer as well as means for the diagnosis of cancer and for the prognosis/detection of an eventual treatment response to agents acting on cancer.
PCT/IB2000/000431 1999-03-29 2000-03-28 Prostate cancer associated human fibronectin gene and biallelic markers WO2000058509A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU41356/00A AU4135600A (en) 1999-03-29 2000-03-28 Prostate cancer associated human fibronectin gene and biallelic markers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12678099P 1999-03-29 1999-03-29
US60/126,780 1999-03-29

Publications (2)

Publication Number Publication Date
WO2000058509A2 WO2000058509A2 (en) 2000-10-05
WO2000058509A3 true WO2000058509A3 (en) 2002-09-12

Family

ID=22426617

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/000431 WO2000058509A2 (en) 1999-03-29 2000-03-28 Prostate cancer associated human fibronectin gene and biallelic markers

Country Status (2)

Country Link
AU (1) AU4135600A (en)
WO (1) WO2000058509A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008046510A1 (en) * 2006-10-16 2008-04-24 Bayer Healthcare Ag Fn1 as a biomarker, therapeutic and diagnostic target
KR101251538B1 (en) 2009-04-17 2013-04-08 (주)아벨리노 Primer for Avellino Corneal Dystrophy
KR101125212B1 (en) 2010-10-01 2012-03-21 (주)아벨리노 System for diagnosis of avellino corneal dystrophy
WO2014144874A1 (en) * 2013-03-15 2014-09-18 Avellino Lab Usa, Inc. Methods for improved isolation of genomic dna templates for allele detection
US10889850B2 (en) 2013-03-15 2021-01-12 Avellino Lab Usa, Inc. Methods for improved isolation of genomic DNA templates for allele detection
AU2014348279B2 (en) 2013-11-15 2021-02-18 Avellino Lab Usa, Inc. Methods for multiplex detection of alleles associated with ophthalmic conditions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999004038A2 (en) * 1997-07-18 1999-01-28 Genset Biallelic markers for use in constructing a high density disequilibrium map of the human genome
US5869241A (en) * 1991-06-27 1999-02-09 Genelabs Technologies, Inc. Method of determining DNA sequence preference of a DNA-binding molecule

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869241A (en) * 1991-06-27 1999-02-09 Genelabs Technologies, Inc. Method of determining DNA sequence preference of a DNA-binding molecule
WO1999004038A2 (en) * 1997-07-18 1999-01-28 Genset Biallelic markers for use in constructing a high density disequilibrium map of the human genome

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DEAN ET AL.: "Forskolin inducibility and tissue-specific expression of the fibronectin promoter", MOLECULAR AND CELLULAR BIOLOGY, vol. 9, no. 4, April 1989 (1989-04-01), pages 1498 - 1506, XP002168436 *
GARDELLA ET AL.: "Human fibronectin gene (FN1) RFLPs: mapping and linkage disequilibrium analysis", HUMAN GENETICS, vol. 92, no. 6, December 1993 (1993-12-01), pages 639 - 641, XP000993547 *
KORNBLIHTT A R ET AL: "PRIMARY STRUCTURE OF HUMAN FIBRONECTIN: DIFFERENTIAL SPLICING MAY GENERATE AT LEAST 10 POLYPEPTIDES FROM A SINGLE GENE", EMBO JOURNAL,GB,IRL PRESS, EYNSHAM, vol. 4, no. 7, 1985, pages 1755 - 1759, XP002051533, ISSN: 0261-4189 *
SAPOLSKY R J ET AL: "High-throughput polymorphism screening and genotyping with high-density oligonucleotide arrays", GENETIC ANALYSIS: BIOMOLECULAR ENGINEERING,US,ELSEVIER SCIENCE PUBLISHING, vol. 14, no. 5-6, February 1999 (1999-02-01), pages 187 - 192, XP004158703, ISSN: 1050-3862 *

Also Published As

Publication number Publication date
AU4135600A (en) 2000-10-16
WO2000058509A2 (en) 2000-10-05

Similar Documents

Publication Publication Date Title
DK1071710T3 (en) Genomic sequence of the 5-lipoxygenase activation protein (FLAP), polymorphic markers therein, and methods for detecting asthma
AU4560499A (en) Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
WO2004111273A3 (en) Gene expression markers for response to egfr inhibitor drugs
WO2004060302A3 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
WO2000050588A3 (en) Genes associated with diseases of the colon
AU1465801A (en) Methods for cancer prognosis and diagnosis
WO2000061622A3 (en) Genes associated with diseases of the kidney
WO2004047514A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2000056924A3 (en) Genomic sequence of the purh gene and purh-related biallelic markers
MXPA02002251A (en) Diagnostics and therapeutics for osteoporosis.
WO2004031414A3 (en) Method for diagnosing prostate cancer
WO2002098355A3 (en) Methods and reagents for diagnosis and treatment of insulin resistance and related conditions
WO2004043232A3 (en) Methods for identifying risk of melanoma and treatments thereof
WO2005014846A3 (en) Methods for identifying risk of breast cancer and treatments thereof
AU6425800A (en) Agents for the diagnosis, prognosis and treatment of malignant diseases
AU2003303379A1 (en) Androgen-regulated genes and uses for diagnosis, prognosis and treatment of prostate neoplastic conditions
EP1108789A3 (en) Quantitation of hTERT mRNA Expression
AU2001263992A1 (en) Method for in vitro diagnosis of prostatic cancer and kit therefor
HK1049682A1 (en) Endo-beta-N-acetylglucosaminidase gene.
WO2001037779A3 (en) A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer
WO2000058509A3 (en) Prostate cancer associated human fibronectin gene and biallelic markers
WO2000022122A3 (en) Genes, proteins and biallelic markers related to central nervous system disease
AU2002219137A1 (en) Diagnosis kit, dna chip, and methods for diagnosing or supervising the treatment of testicular cancer
WO2001009384A3 (en) Serial analysis of genetic alterations
WO2001007644A3 (en) Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP